It all starts with the
of new modes of action

Target discovery platform

Filgotinib, a selective JAK1-inhibitor which has shown activity and favorable tolerability in inflammatory diseases.

A tiny molecule – yet,
what it can do is


GLPG1690, a potent and selective inhibitor of autotaxin, a potential target for IPF.

Innovative medicines
can change
people’s lives

The Galapagos pipeline

As many
have done before


Clockwise: single microscope, Antoni van Leeuwenhoek (1673-1723); heart valve prosthesis (1970-1990); artificial kidney, Willem Johan Kolff (1943); bottle with penicillin, Royal Dutch Yeast and Spiritus factory (1950-1975); hearing aid (1875-1950).

To date, we have
three novel
showing promising
patient results


Clockwise: small molecule filgotinib, small molecule GLPG1690 and monoclonal antibody MOR106.

This is just
the beginning

Letter from the management

Financial highlights

Group revenues

155.9 million

Read more

Cash position

1152.4 million

Read more

Letter from the management

We look back on another very successful execution year at Galapagos. But this is just the beginning. We continue to discover new modes of action, and plan to bring them all the way to patients.
Read more

Corporate social responsibility

We believe we have a responsibility to ensure our actions not only benefit our main stakeholders, but also society as a whole. At Galapagos, being socially responsible is already a consideration in everything we do.

Read more